Cancers, Vol. 16, Pages 1226: T-Cell Subtypes and Immune Signatures in Cutaneous Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy
In conclusion, we identified distinct immune signatures based on the Th17/Th22 pathway in cutAEs, both in PBMCs and plasma. In addition, our finding of upregulated IL-10 during cutAEs supports the notion of treating these patients early and adequately to avoid implications for the overall outcome. (Source: Cancers)
Source: Cancers - March 20, 2024 Category: Cancer & Oncology Authors: Magdalena Absmaier-Kijak Caterina Iuliano Susanne Kaesler Tilo Biedermann Christian Posch Knut Brockow Tags: Article Source Type: research
Association between gut microbiota and pan-dermatological diseases: a bidirectional Mendelian randomization research
ConclusionThis study provides novel insights into the causality of gut microbiota in dermatological diseases and therapeutic or preventive paradigms for cutaneous conditions. (Source: Frontiers in cellular and infection microbiology)
Source: Frontiers in cellular and infection microbiology - March 18, 2024 Category: Microbiology Source Type: research
Bruton's tyrosine kinase inhibition for the treatment of allergic disorders
Ann Allergy Asthma Immunol. 2024 Mar 14:S1081-1206(24)00145-5. doi: 10.1016/j.anai.2024.03.002. Online ahead of print.ABSTRACTIgE signaling through its high-affinity receptor FcεRI is central to the pathogenesis of numerous allergic disorders. Oral inhibitors of Bruton's tyrosine kinase (BTKis), which are currently FDA-approved for the treatment of B cell malignancies, broadly inhibit the FcεRI pathway in human mast cells and basophils and therefore may be effective allergen-independent therapies for a variety of allergic diseases. The application of these drugs to the allergy space was previously limited by the low kina...
Source: Annals of Allergy, Asthma and Immunology - March 16, 2024 Category: Allergy & Immunology Authors: Erica V Lin Ragha V Suresh Melanie C Dispenza Source Type: research
Bruton's tyrosine kinase inhibition for the treatment of allergic disorders
Ann Allergy Asthma Immunol. 2024 Mar 14:S1081-1206(24)00145-5. doi: 10.1016/j.anai.2024.03.002. Online ahead of print.ABSTRACTIgE signaling through its high-affinity receptor FcεRI is central to the pathogenesis of numerous allergic disorders. Oral inhibitors of Bruton's tyrosine kinase (BTKis), which are currently FDA-approved for the treatment of B cell malignancies, broadly inhibit the FcεRI pathway in human mast cells and basophils and therefore may be effective allergen-independent therapies for a variety of allergic diseases. The application of these drugs to the allergy space was previously limited by the low kina...
Source: Annals of Allergy, Asthma and Immunology - March 16, 2024 Category: Allergy & Immunology Authors: Erica V Lin Ragha V Suresh Melanie C Dispenza Source Type: research
Comparing transfusion reactions between pre-storage and post-storage leukoreduced apheresis platelets: an analysis using propensity score matching
This study suggests pre-storage leukoreduction apheresis platelet significantly decreases the transfusion reaction as compared with those in post-storage leukoreduction. (Source: Annals of Hematology)
Source: Annals of Hematology - March 15, 2024 Category: Hematology Source Type: research
The autologous serum skin test (ASST) predicts the response to anti-IgE treatment in Chronic Spontaneous Urticaria patients: a prospective study
Conclusions. Although larger prospective studies are needed to confirm these results, this study confirms previous retrospective investigations that the positive ASST appears to predict a slow response to omalizumab in CSU patients.PMID:38482859 | DOI:10.23822/EurAnnACI.1764-1489.337 (Source: European Annals of Allergy and Clinical Immunology)
Source: European Annals of Allergy and Clinical Immunology - March 14, 2024 Category: Allergy & Immunology Authors: A Palladino F Villani E Pinter M Visentini R Asero Source Type: research
